NasdaqGM:VCELBiotechs
Vericel (VCEL) Valuation Check After Updated 2025 Guidance And Profitability Outlook
Updated guidance shifts attention to Vericel
Vericel (VCEL) has put out preliminary unaudited guidance for the fourth quarter and full year 2025, flagging 23% revenue growth for the quarter and an expected US$276 million in net revenue for the year.
The company also anticipates GAAP net income profitability for a second straight year, a detail many investors watch closely when considering how a commercial stage biotech is converting its product portfolio into earnings.
See our latest analysis...